A number of CD37-based therapeutics are currently undergoing investigation in CLL, including otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein [8]. This evidence concerns the gene CD37 and B-cell chronic lymphocytic leukemia.